Compare Mesoblast Limited (MESO) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Match Group Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while Match Group Inc trades at $41.48 (market cap $9.37B). The key difference: Match Group Inc is far larger — about 5.2× Mesoblast Limited's market cap, and Match Group Inc pays a 1.96% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Match Group Inc for 115 Days on average.
| MESO | MTCH | |
|---|---|---|
Market Cap | $1.81B | $9.37B |
Volume | 240,620 | 2,544,041 |
Sector | Health | Media |
52-Week High | $20.96 | $44.40 |
52-Week Low | $13.19 | $28.90 |
Typical Hold Time | 14 Days | 115 Days |
Enterprise Value | $1.89B | $12.34B |
Dividend Yield | — | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Match Group (MTCH) trades at $41.50, up 2.17% with a bullish technical outlook. The stock shows strong fundamentals with 74.8% gross margins and consistent earnings beats in recent quarters. Revenue remains stable at $3.5B while net income margin improved to 20.17% in 2025. Analyst consensus is bullish with a $42.29 price target, and institutional activity shows continued interest despite recent selling by some advisors.
MTCH presents a compelling investment case with reasonable valuation (P/E 14.48) and strong cash flow generation. Key risks include high debt levels ($3.85B) and competitive pressures in the dating app market. The company's product innovation and Hinge's growth provide upside potential, though execution risks and market saturation concerns warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
